瑞舒伐他汀治疗临床期糖尿病肾病疗效观察  

Observation of the therapeutic effects of rosuvastatin on clinical-stage diabetic nephropathy

作　　者：陶松青[1] 陈严文[1] 李海涛[1] 何劲松[2] 

机构地区：[1]江苏省泰兴市人民医院,江苏泰兴225400 [2]南京大学医学院附属鼓楼医院,江苏南京210008

出　　处：《现代中西医结合杂志》2014年第31期3441-3443,共3页Modern Journal of Integrated Traditional Chinese and Western Medicine

摘　　要：目的观察瑞舒伐他汀治疗2型糖尿病临床期肾病的疗效,探讨瑞舒伐他汀肾保护作用的机制。方法将62例2型糖尿病临床期肾病患者随机分为2组,对照组31例给予常规治疗,治疗组31例在常规治疗基础上加用瑞舒伐他汀10 mg/d,疗程8周。观察2组治疗前后血糖、血脂、肾功能、24 h尿蛋白定量(24hU-Pr)、血白蛋白(ALB)和超敏C反应蛋白(hs-CRP)等指标的变化。结果治疗前2组血清总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)、三酰甘油(TG)、空腹血糖(FBG)、糖化血红蛋白(HbA1c)、24hU-Pr、ALB、血清肌酐(SCr)、肾小球滤过率及hs-CRP比较差异均无统计学意义(P均>0.05);治疗后治疗组TC、LDL-C、TG、24hU-Pr、hs-CRP与对照组相比明显降低(P均<0.01),HDL-C明显升高(P<0.01),而FBG、HbA1c、ALB、SCr、肾小球滤过率比较差异无统计学意义(P均>0.05)。结论瑞舒伐他汀在有效降脂的同时,可直接或间接抑制临床期糖尿病肾病患者hs-CRP的表达,减少患者24 h尿蛋白排泄,起到一定的肾脏保护作用。Objective It is to observe the clinical efficacy of rosuvastatin on clinical-stage diabetic nephropathy and to explore the mechanism of rosuvastatin in the renal protective effect. Methods 62 patients of clinical stage of diabetic nephropathy in type 2 diabetes mellitus were randomly divided into two groups： treatment group and control group. The control group of 31 cases were given conventional treatment,the treatment group of 31 cases were added with rosuvastatin 10 mg /d on the basis of conventional therapy,the treatment courses were lasted for 8 weeks. The changes of blood glucose,blood lipid,renal function,24 h urinary protein,serum albumin and hs- CRP index were observed in both group before and after treatment. Results Before treatment,there was no significant difference in the levels of total cholesterol（ TC）,low density lipoprotein（ LDL-C）,high density lipoprotein（ HDL- C）,triglyceride（ TG）,fasting blood glucose（ FBG）,glycosylated hemoglobin A1c（ HbA1c）,24 hour urinary protein quantitative（ 24hU- Pr）,serum albumin（ ALB）,serum creatinine（ SCr）,glomerular filtration rate（ GFR） and hs- CRP between the two groups（ P〉 0.05）; after treatment,TC,LDL- C,TG,24hU- Pr,hs-CRP decreased significantly compared with the control group（ P〈0.01）,HDL- C significantly increased（ P〈0.01）,but no statistical significant differences in FBG,HbA1 c,ALB,SCr,GFR was found（ P〉 0.05）. Conclusion Rosuvastatin can effectively decrease blood lipid,at the same time,it also can inhibit expression of hs- CRP in patients with clinical stage diabetic nephropathy directly or indirectly,reduce urinary protein excretion of 24 h,so as to play some protective effect of kidney.

关 键 词：瑞舒伐他汀 糖尿病肾病 胆固醇 尿蛋白 高敏C反应蛋白 

分 类 号：R587.1[医药卫生—内分泌]